On May 10th, the annual top list from China Venture was announced. With a professional investment philosophy and excellent investment return performance, TTM Capital was awarded the top 50 best early-stage venture capital institutions in China for 2023.

Rooted in fertile soil, united in strength, and working hand in hand for mutual success. The recognition is prestigious acknowledgment for TTM Capital. Since the operation of TTM's first fund in March 2022, it has demonstrated outstanding investment returns despite the increasing difficulty of market exits: the star project XinThera was acquired by an internationally renowned pharmaceutical company just one year after the fund's investment, achieving nearly 10 times the return; the overall IRR of the project is over 200%, and the fund's DPI is nearly 40%.

TTM Capital has always focused on deep cooperation with ecological partners to jointly address challenges, adhering to the investment philosophy of " Comprehensive linkage, multi-disciplinary sourcing, strategic alliance," promoting the globalization process of medical enterprises, and helping companies step onto the international stage.

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.